Published in J Alzheimers Dis on April 04, 2016
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol (2007) 17.69
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Forecasting the global burden of Alzheimer's disease. Alzheimers Dement (2007) 10.01
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA (2000) 6.55
Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science (1990) 6.03
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci (1993) 4.60
Plaques, tangles and dementia. A quantitative study. J Neurol Sci (1982) 4.52
The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J Neuropathol Exp Neurol (1996) 4.39
In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem (2002) 4.20
Structural classification of toxic amyloid oligomers. J Biol Chem (2008) 4.16
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
A three-dimensional human neural cell culture model of Alzheimer's disease. Nature (2014) 3.48
Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging (2004) 3.13
A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods (1998) 2.79
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc Natl Acad Sci U S A (2013) 2.45
Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science (1989) 1.69
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener (2013) 1.35
Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol (2013) 1.31
Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (1987) 1.22
The case for rejecting the amyloid cascade hypothesis. Nat Neurosci (2015) 1.21
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion (2012) 1.11
Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med (2010) 0.99
Effects of the monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation and differentiation of adult neural stem cells from subventricular zone. J Neurochem (2007) 0.98
Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett (1990) 0.98
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Curr Opin Psychiatry (2014) 0.96
Beta-amyloid(Phe(SO3H)24)25-35 in rat nucleus basalis induces behavioral dysfunctions, impairs learning and memory and disrupts cortical cholinergic innervation. Behav Brain Res (1998) 0.91
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement (2015) 0.89
Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (BAY x 3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience (2001) 0.87
Simultaneous multiple synthesis and selective conjugation of cyclized peptides derived from a surface loop of a meningococcal class 1 outer membrane protein. Int J Pept Protein Res (1994) 0.87
Intra-peritoneal injection of polyclonal anti-interferon alpha antibodies cross the blood brain barrier and neutralize interferon alpha. Neurochem Res (2008) 0.86
LPYFDa neutralizes amyloid-beta-induced memory impairment and toxicity. J Alzheimers Dis (2010) 0.84
Postnatal treatment with ACTH-(4-9) analog ORG 2766 attenuates N-methyl-D-aspartate-induced excitotoxicity in rat nucleus basalis in adulthood. Eur J Pharmacol (2000) 0.84
Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology (2010) 0.83
Amyloid beta peptide immunotherapy in Alzheimer disease. Rev Neurol (Paris) (2014) 0.83
Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother (2014) 0.82
Large quantities of Abeta peptide are constitutively released during amyloid precursor protein metabolism in vivo and in vitro. J Biol Chem (2011) 0.81
Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA. J Immunoassay (1997) 0.81
Pretreatment with lovastatin prevents N-methyl-D-aspartate-induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction. J Alzheimers Dis (2009) 0.80
Monophosphoryl lipid A is an lipopolysaccharide-derived Toll-like receptor 4 agonist which may improve Alzheimer's disease pathology. Expert Opin Biol Ther (2013) 0.80
Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration (1995) 0.78
A cyclic undecamer peptide mimics a turn in folded Alzheimer amyloid β and elicits antibodies against oligomeric and fibrillar amyloid and plaques. PLoS One (2011) 0.78
Tailoring the antibody response to aggregated Aß using novel Alzheimer-vaccines. PLoS One (2015) 0.76